Protagonist Therapeutics' new drug targets the same mechanism as an existing development.
1 report, 0 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Protagonist Therapeutics' new drug targets the same mechanism as an existing development.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Protagonist Therapeutics (United States)
company in Milpitas, United States
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly and Company is expanding into psychedelic and neuroscience pipelines, adding late-stage psychedelic assets through acquisition.
- Eli Lilly and Company developed the drug Retatrutide.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- Eli Lilly and Merck are combining therapies in clinical trials.
Coverage
Newest first; wire copies grouped- Unknown outlet